Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial Intelligence-Powered Radiotherapy for Resource-Limited Settings: Advancing Cervical and Prostate Cancer Treatment Planning With the Radiation Planning Assistant.

JCO global oncology·2026
Same author

Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Advancements in Accelerator and Beam Delivery Technology.

Cancer journal (Sudbury, Mass.)·2026
Same author

Artificial Intelligence in Triple-Negative Breast Cancer: Applications in Diagnosis, Treatment Response, and Prognosis.

Diagnostics (Basel, Switzerland)·2026
Same author

Defining a Quantitative Threshold for Adaptive Re-planning using a Percentile-based Scoring System.

International journal of particle therapy·2026

Related Experiment Video

Updated: Jul 3, 2025

Author Spotlight: An Efficient and Robust Software for Automated Fusion of Multiple Preclinical Imaging Modalities
07:13

Author Spotlight: An Efficient and Robust Software for Automated Fusion of Multiple Preclinical Imaging Modalities

Published on: October 27, 2023

1.1K

A Novel Polymer-Encapsulated Multi-Imaging Modality Fiducial Marker with Positive Signal Contrast for Image-Guided

Li Wang1, Jeremiah Sanders2, John F Ward3

  • 1Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Cancers
|February 10, 2024
PubMed
Summary

A novel fiducial marker (FM), NOVA, offers improved visualization across multiple imaging modalities and reduces radiation dose perturbation compared to existing markers for prostate cancer radiotherapy.

Keywords:
NOVAfiducial markermagnetic resonance imagingprostate cancerradiation therapy

More Related Videos

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

15.7K
Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers
12:24

Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers

Published on: July 17, 2012

12.4K

Related Experiment Videos

Last Updated: Jul 3, 2025

Author Spotlight: An Efficient and Robust Software for Automated Fusion of Multiple Preclinical Imaging Modalities
07:13

Author Spotlight: An Efficient and Robust Software for Automated Fusion of Multiple Preclinical Imaging Modalities

Published on: October 27, 2023

1.1K
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

15.7K
Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers
12:24

Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers

Published on: July 17, 2012

12.4K

Area of Science:

  • Medical Physics
  • Radiotherapy Technology
  • Oncology Imaging

Background:

  • Current fiducial markers (FMs) for prostate cancer (PCa) external-beam radiotherapy (EBRT) have limitations in MRI visualization and cause artifacts/dose perturbations.
  • Novel multimodality FM, NOVA, was developed to address these limitations.

Purpose of the Study:

  • To evaluate the imaging characteristics and dosimetric properties of the NOVA FM.
  • To compare NOVA FMs with existing Gold Anchor (G-FM) and BiomarC (C-FM) markers.

Main Methods:

  • Phantoms with G-FM, C-FM, and NOVA FMs were imaged using kV X-ray, TRUS, CT, and MRI.
  • CT artifacts were quantified using the relative streak artifacts level (rSAL) metric.
  • Proton dose perturbations (PDPs) were measured with Gafchromic film at varying depths and orientations relative to the beam axis.

Main Results:

  • NOVA FMs were visualized on all tested imaging modalities.
  • NOVA FMs produced significantly less proton dose perturbation (4.5%) at 5-mm depth compared to G-FM (12.9%) and C-FM (6.0%).
  • Clinical use in a patient demonstrated feasibility and reproducibility for MRI/CT co-registration and daily alignment in EBRT planning.

Conclusions:

  • NOVA FMs offer superior visibility and reduced dose perturbation compared to G-FMs and C-FMs.
  • NOVA FMs facilitate MRI/CT fusion and accurate identification of treatment regions in prostate cancer radiotherapy.